Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CabOSTar maintenance cabozantinib versus best supportive care in children and AYA with osteosarcoma
NL-OMON61204Phase 2Completed
- Sponsor
- Ipsen
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cabozantinib in osteosarcoma (OS) (2 arms), sponsored by Ipsen. Primary endpoint: Progression-free survival assessed by BIRC. Started Jun 2024; status: completed.
02
Drugs
cabozantinib
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NL-OMON61204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61204.